Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Clinical Pharmacology and Therapeutics|December 12, 2017
Designing In and Around Tolerability Considerations for Immunotherapy CombinationsMark StrohClinical Pharmacology and Therapeutics|July 10, 2023
Clinical Pharmacology and Translational Considerations in the Development of CRISPR-Based TherapiesAhmed M Abdelhady, Jonathan A Phillips, Yuanxin Xu, et al.Cancer Chemotherapy and Pharmacology|January 14, 2016
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancerMark Stroh, Michelle Green, Edward Cha, et al.The AAPS Journal|January 29, 2013
Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolitesMark Stroh, Matthew M Hutmacher, Jianmei Pang, et al.Biophysical Journal|June 28, 2003
Diffusion of nerve growth factor in rat striatum as determined by multiphoton microscopyMark Stroh, Warren R Zipfel, Rebecca M Williams, et al.The AAPS Journal|December 29, 2016
Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung CancerKelong Han, Pascal Chanu, Fredrik Jonsson, et al.Cancer Chemotherapy and Pharmacology|December 28, 2014
Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancerMarie T Borin, Meng Chen, Simonetta Mocci, et al.Nature Materials|June 23, 2004
Multiphoton microscopy guides neurotrophin modification with poly(ethylene glycol) to enhance interstitial diffusionMark Stroh, Warren R Zipfel, Rebecca M Williams, et al.CPT: Pharmacometrics & Systems Pharmacology|June 29, 2019
Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated AntibodyMark Stroh, Jason Sagert, John M Burke, et al.Clinical Pharmacology and Therapeutics|July 31, 2018
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer PatientsIda Netterberg, Chi-Chung Li, Luciana Molinero, et al.Pageof 4